Public Companies
Filament Health Announces Spring 2023 Event and Media Appearances
Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced upcoming event…
Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced upcoming event appearances and media coverage for Spring 2023.
EVENTS
- Filament CEO and Co-Founder Benjamin Lightburn has been invited to speak at MAPS Psychedelic Science Conference in Denver. Mr. Lightburn will participate in a panel entitled “The Future of Psychedelic Manufacturing” on Friday, June 23.
- Filament will also exhibit in the conference hall at booth #310.
- Mr. Lightburn will also speak at the Psychedelic Therapeutics and Drug Development Conference in San Francisco on May 15, with a presentation titled “The Natural Advantage: A Novel Approach to Approval.”
MEDIA
- On Wednesday, April 27, at 8:10 a.m. ET, Mr. Lightburn will appear on CTV’s Your Morning to discuss the Company’s recent development of GMP MDMA capsules.
- On Saturday, April 15, Filament was featured in The Globe & Mail, highlighting the recent development of pharmaceutical grade MDMA. Click here to read the article.
- On Monday, April 17, Mr. Lightburn spoke to CKNW Global News Radio about Filament’s efforts to improve access to MDMA for mental health treatment. Click here to listen.
VIRTUAL INVESTOR UPDATE
- On Thursday, May 18, at 11:00 a.m. PT / 2:00 p.m. ET, Filament will host a virtual update for shareholders and investors.
- Filament’s executive team will discuss recent progress and plans for the future, followed by a live question and answer period.
- Contact Anna Cordon at anna@filament.health to RSVP.
ABOUT FILAMENT HEALTH
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with the first-ever natural psychedelic drug candidates.
-
LSD1 week agoThe First Wave of Blotter Acid Inspired Trippy Psychedelic Art
-
Psilocybin1 week agoPsychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics5 days agoCompass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics5 days agoCybin to Participate at the 27th Annual Milken Institute Global Conference
-
Psychedelics4 days agoFreedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Psychedelics4 days agoAre ‘Ketamine Bros’ Ruining It for Everyone Else?
-
Psychedelics4 days agoBehold! A New Mushroom Emoji Has Arrived!
-
Psychedelics4 days ago
Behold! A New Mushroom Emoji Has Arrived!